NCT00408213View on ClinicalTrials.gov

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

PHASE3CompletedINTERVENTIONAL

Enrollment

136

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

September 30, 2007

Conditions

Myasthenia Gravis Generalised

Interventions

DRUG

mycophenolate mofetil [CellCept]

1g po bid

DRUG

Placebo

po bid

Trial Locations (16)

185

Roma

11000

Belgrade

19013

Upland

20133

Milan

61068

Kharkiv

81675

München

85351

Sun City

93053

Regensburg

95817

Sacramento

Unknown

Bordeaux

Nice

Kiev

Zaporizhzhya

L9 1AE

Liverpool

OX2 6HE

Oxford

M6 8HD

Salford

Sponsors

Collaborators (1)

Aspreva Pharmaceuticals

All Listed Sponsors

collaborator

Aspreva Pharmaceuticals

INDUSTRY

lead

Hoffmann-La Roche

INDUSTRY

NCT00408213 - A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis. | Biotech Hunter | Biotech Hunter